Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene, ENSG00000225370 (AC243962.1), is annotated as a **pseudogene similar to leukocyte immunoglobulin-like receptor** in Homo sapiens. Pseudogenes are genomic DNA sequences similar to normal genes but generally nonfunctional due to mutations, truncations, or other errors. This locus does not encode a functional protein and is not considered a therapeutic target. It shares homology with the family of leukocyte immunoglobulin-like receptors (LILRs), which comprise a group of regulatory receptors involved in immune modulation, but itself lacks a known protein product or biological activity, and is not implicated in immune signaling or disease[1][3][5]. **Notes and Justification:** - This entry is not a true drug target, nor is it a functional receptor, enzyme, or therapeutic molecule—it is a **pseudogene** with no evidence of protein expression or direct biological function[1][3]. - The description and aliases in gene databases confirm its status as a pseudogene; thus it is **not a target and is_incorrect (for therapeutic considerations) is true**[1][3][5]. - The pseudogene is called "leukocyte immunoglobulin-like receptor pseudogene 1" in some listings, but this is not a functional receptor[2][5]. - There are no drugs, mechanisms of action, or biomarker uses associated with this pseudogene. - For molecular and disease classification, "Other" is used because pseudogenes are generally cataloged separately from protein-coding genes and functional noncoding RNAs. **If an active, functional member of the leukocyte immunoglobulin-like receptor family is required (e.g., LILRB2, LILRA2), those are separate protein-coding genes with immune regulatory and disease relevance[4][6][7][9].**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to leukocyte immunoglobulin-like receptor.